BVF Partners ELDN Position
Active3-Fund ConvergenceBVF Partners held their position in Eledon Pharmaceuticals, Inc. (ELDN) in Q4 2025, holding $9.5M worth of shares across 6,293,282 shares.
The position was first reported in Q1 2023 and has been tracked across 12 quarterly 13F filings.
ELDN is a convergence signal: 3 specialist biotech funds hold this stock, suggesting high institutional conviction.
Short interest stands at 12.1% of float with 7.7 days to cover, indicating significant bearish positioning against BVF's long thesis.
About Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that is a molecule expressed on the surface of human immune system T cells, which is in Phase 2a clinical trials for the treatment of ALS, and Phase 2 clinical trials in islet cell transplantation for the treatment of type 1 diabetes. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.
Full company profile →Short Interest
12.1%
7.7 days to cover
BVF Partners ELDN Position History
| Quarter | Action | Shares | Change | Value |
|---|---|---|---|---|
| Q4 2025 | Held | 6,293,282 | — | $9.5M |
| Q3 2025 | Held | 6,293,282 | — | $16.3M |
| Q2 2025 | Held | 6,293,282 | — | $17.1M |
| Q1 2025 | Held | 6,293,282 | — | $21.3M |
| Q4 2024 | Held | 6,293,282 | — | $25.9M |
| Q3 2024 | Held | 6,293,282 | — | $15.7M |
| Q2 2024 | Increased | 6,293,282 | +1,966,572 | $16.6M |
| Q1 2024 | Held | 4,326,710 | — | $8.9M |
| Q4 2023 | Held | 4,326,710 | — | $7.8M |
| Q3 2023 | Held | 4,326,710 | — | $5.9M |
| Q2 2023 | Increased | 4,326,710 | +2,000,000 | $5.9M |
| Q1 2023 | New | 2,326,710 | +2,326,710 | $5.5M |
Frequently Asked Questions
Does BVF Partners own ELDN?
Yes. As of Q4 2025, BVF Partners holds 6,293,282 shares of Eledon Pharmaceuticals, Inc. (ELDN) valued at $9.5M. This data comes from their SEC 13F filing.
How many hedge funds own ELDN?
3 specialist biotech hedge funds currently hold ELDN, including RA Capital Management, Cormorant Asset Management. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did BVF Partners first buy ELDN?
BVF Partners's position in ELDN was first reported in Q1 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is BVF Partners's ELDN position increasing or decreasing?
BVF Partners held their ELDN position unchanged in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
ELDNCompany Page →
All fund holders, insider trades, catalysts, and cash runway
BVF PartnersPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →